Denver, CO , March 01, 2018 -- Ubiquitech Software Corp. (OTC: UBQU), through its operating subsidiary HempLifeToday.com, today announced its fourth quarter and fiscal year end 2017 financial results. Revenues for the quarter increased to $1,237,656, and to $4,514,104 for the year. The company had net income of $352,447 for the year ending November 30, 2017.
CEO James Ballas said “We are extremely happy to continue to grow and strengthen the company. This marks the fourth consecutive year of double digit revenue growth. The CannazALL brand continues to expand its presence in the growing CBD marketplace, and the Company continues to add new and inventive offerings to this product line. We look forward to our impending launch of our CryptoBuy division and the excitement that it will bring to the Company.”
About Ubiquitech Software Corp
Ubiquitech Software Corp, through its subsidiaries is a dynamic multi-media, multi-faceted corporation utilizing state-of-the-art global internet marketing, DirectResponse (DRTV) Television, Radio, Internet Content, and traditional marketing to drive traffic to the new and emerging multi-billion dollar industries like its subsidiaries HempLifeToday™ and CryptoBuy.com
About HempLife Today™
HempLifeToday™ focuses on the exciting and dynamic new thinking in the world today that recognizes the important health and life enriching enhancement that CBD Oil from the Hemp plant can bring. Through its network of quality USA growers HempLifeToday.com™ has developed multiple and proprietary CannazALL™ CBD oil products that include; It’s popular CBD Tinctures, Concentrated Oils, GelCaps, Skin Salve, e-liquid, and CannazALL Pets™ CBD products all offered @ www.HempLifeToday.com
About CryptoBuy
CryptoBuy.com focuses on the burgeoning new world of Crypto Currencies and is created to be a service to persons interested in tracking and trading the many existing and future Crypto Currencies worldwide.
This press release contains forward-looking statements. Words such as "expects", "intends'', "believes'', and similar expressions reflecting something other than historical fact are intended to identify forward-looking statements, but are not the exclusive means of identifying such statements. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, the ability to secure additional sources of finance, the ability to reduce operating expenses, and other factors described in the Company's filings with the OTC Markets Group. The actual results that the Company achieves may differ materially from any forward-looking statement due to such risks and uncertainties. The Company undertakes no obligation to revise or update any forward- looking statements in order to reflect events or circumstances that may arise after the after the date of this release.
Contact: Ubiquitech Software Corp Investor relations [email protected]


Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
OpenAI Restricts Astra AI Over Cyberattack Risks
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
DeepSeek to Raise AI API Prices as Demand for New Models Surges
Airbnb Stock Jumps After Q2 Earnings Beat, Strong 2026 Outlook
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 



